Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A3907 in Adults with Primary Sclerosing Cholangitis
2022-500790-14-00Phase 2Completed
- Sponsor
- Albireo Pharma
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of Ritivixibat in Primary Sclerosing Cholangitis (PSC) (4 arms), sponsored by Albireo Pharma. Primary endpoint: Safety and tolerability (TEAEs through Week 12). Started Dec 2022; status: completed.
02
Drugs
Ritivixibat
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on 2022-500790-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500790-14-00.